Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Institut Curie maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently facing 3 pending office actions. These actions are spread across 3 distinct examiners, which means each pending matter is being reviewed by a different official. This distribution requires the company to address separate examiner perspectives simultaneously.
The portfolio's current activity involves 2 distinct art units within the Biotechnology & Pharmaceuticals sector. TRAN, ERIC is the busiest examiner for the company, currently overseeing 1 of the pending office actions. Since there are 3 pending office actions in total, the remaining actions are handled by the other distinct examiners. This structure indicates that the workload is not concentrated under any single individual.
The involvement of 2 distinct art units suggests that the biotechnology filings cover specialized sub-fields. Practitioners should note that TRAN, ERIC handles 1 pending action, requiring a tailored approach for that specific matter. Successfully navigating these 3 pending office actions will require consistent messaging across the 3 distinct examiners to protect the company's pharmaceutical innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, ERIC | 1 | 70.8% | +23.3% |
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284253 | PREPARATION METHOD OF QUINOLINE DERIVATIVE COMPOUNDS | REILLY, SOPHIA JANE | 20d |
| 18686403 | NITROGEN-CONTAINING DERIVATIVES OF NARASIN, SYNTHESIS AND USES THEREOF | TRAN, ERIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284253 | PREPARATION METHOD OF QUINOLINE DERIVATIVE COMPOUNDS | REILLY, SOPHIA JANE | 20d |
| 18686403 | NITROGEN-CONTAINING DERIVATIVES OF NARASIN, SYNTHESIS AND USES THEREOF | TRAN, ERIC | — |
| 18684020 | USE OF ETV3 OR ETV6 INHIBITORS FOR BLOCKING THE DIFFERENTIATION OF MONOCYTES INTO DENDRITIC CELLS | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686403 | NITROGEN-CONTAINING DERIVATIVES OF NARASIN, SYNTHESIS AND USES THEREOF | TRAN, ERIC | 1629 | §103§112 | Final Rejection | — | Pending | Feb 23, 2024 |
| 18684020 | USE OF ETV3 OR ETV6 INHIBITORS FOR BLOCKING THE DIFFERENTIATION OF MONOCYTES INTO DENDRITIC CELLS | KONOPKA, CATHERINE ANNE | — | §103 | Final Rejection | — | Pending | Feb 15, 2024 |
| 18284253 | PREPARATION METHOD OF QUINOLINE DERIVATIVE COMPOUNDS | REILLY, SOPHIA JANE | 1627 | §103§112 | Final Rejection | 20d | Pending | Sep 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial